Research

Hormonal

Semaglutide 2.4 mg combined with diet and exercise is cost-effective for adults with obesity (BMI ≥ 30 kg/m²) and comorbidities in Portugal, yielding 0.098 QALYs gained at an ICER of 13,459 EUR per QALY compared to diet and exercise alone.

For patients with obesity and comorbidities in Portugal, adding semaglutide 2.4 mg to diet and exercise is a cost-effective strategy that improves quality-adjusted life years compared to diet and exercise alone, particularly for those with BMI ≥ 30 kg/m².

GoodSupportsHIGH confidence
On a patient level, Semaglutide 2.4 mg in addition to D&E compared to D&E alone, improved QALYs by 0.098 and yielded higher costs by 1,325 EUR over a 40-year time horizon, with an ICER of 13,459 EUR per QALY gained and 100% probability of cost-effectiveness at the given WTP.
Luís Silva Miguel et al. · Diabetology & Metabolic Syndrome · 2024

Why this rating

Based on a validated Markov model using data from Phase 3 STEP trials, though it is a modeling study rather than a direct long-term RCT.

Source

Cost-effectiveness of semaglutide 2.4 mg in chronic weight management in Portugal

Luís Silva Miguel et al. · Diabetology & Metabolic Syndrome · 2024

DOI 10.1186/s13098-024-01338-4

unknown · n=1470Cited 13×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →